Abstract
We sought to validate levels of CD8+ tumor-infiltrating cells (TIC) expressing PD-1 but not TIM-3 and LAG-3 (IF biomarker; Pignon and colleagues, 2019) and to investigate human endogenous retroviruses (hERV) as predictors of response to anti-PD-1 in a randomized trial of nivolumab (nivo) versus everolimus (evero) in patients with metastatic clear cell renal cell carcinoma (mccRCC; CheckMate-025). Tumor tissues (nivo: n = 116, evero: n = 107) were analyzed by multiparametric immunofluorescence (IF) and qRT-PCR. Genomic/transcriptomic analyses were performed in a subset of samples. Clinical endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and durable response rate (DRR, defined as complete response or partial response with a PFS ≥ 12 months). In the nivo (but not evero) arm, patients with high-IF biomarker density (24/116, 20.7%) had higher ORR (45.8% vs. 19.6%, P = 0.01) and DRR (33.3% vs. 14.1%, P = 0.03) and longer median PFS (9.6 vs. 3.7 months, P = 0.03) than patients with low-IF biomarker. By RNA sequencing, several inflammatory pathways (q < 0.1) and immune-related gene signature scores (q < 0.05) were enriched in the high-IF biomarker group. When combined with the I...Continue Reading
References
Jan 1, 1950·Cancer·W J YOUDEN
Dec 2, 2008·Nature Immunology·Shawn D BlackburnE John Wherry
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 8, 2010·The Journal of Experimental Medicine·Kaori SakuishiAna C Anderson
May 24, 2011·Oncogene·E CherkasovaR W Childs
Jan 18, 2013·BMC Bioinformatics·Sonja HänzelmannJustin Guinney
Jan 17, 2015·Cell·Michael S RooneyNir Hacohen
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Jan 16, 2016·Cell Systems·Arthur LiberzonPablo Tamayo
Feb 11, 2016·Cancer Research·Elena CherkasovaRichard W Childs
Aug 9, 2016·Nature·Se Jin ImRafi Ahmed
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
Jun 6, 2018·Nature Medicine·David F McDermottThomas Powles
Jun 23, 2018·Journal for Immunotherapy of Cancer·Patrick DanaherAlessandra Cesano
Aug 24, 2018·JCI Insight·Anshuman PandaW Kimryn Rathmell
Aug 24, 2018·The Journal of Clinical Investigation·Christof C SmithBenjamin G Vincent
Nov 6, 2018·Cell·Moshe Sade-FeldmanNir Hacohen
Jan 13, 2019·Immunity·Imran SiddiquiWerner Held
Jan 24, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Christophe PignonSabina Signoretti
Feb 7, 2019·Nature Reviews. Cancer·Peter A JonesDaniel D De Carvalho
Feb 14, 2019·Nature Reviews. Cancer·Jonathan J HavelTimothy A Chan
Feb 20, 2019·Nature Immunology·Brian C MillerW Nicholas Haining
May 8, 2019·Nature Biotechnology·Aaron M NewmanAsh A Alizadeh
Aug 14, 2019·Frontiers in Immunology·Nadine S JahchanMatthew F Krummel
Dec 13, 2019·Nature·Caroline S JansenHaydn Kissick
Jan 17, 2020·Nature·Rita CabritaGöran Jönsson
Jan 17, 2020·Nature·Beth A HelminkJennifer A Wargo
Jan 17, 2020·Nature·Florent PetitprezWolf H Fridman
May 28, 2020·Frontiers in Immunology·Florent PetitprezWolf H Fridman
May 31, 2020·Nature Medicine·David A BraunToni K Choueiri
Citations
May 11, 2021·Frontiers in Oncology·Veronika WeyererReiner Strick
Aug 21, 2021·Frontiers in Oncology·Xinyuan LiFu Liu
Jun 26, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla CalaguaDavid J Einstein
Oct 16, 2021·Cancer Discovery·Raymond ChenDaniel D De Carvalho